miR-200b 与癌症化疗敏感性的研究综述。

Review of miR-200b and cancer chemosensitivity.

机构信息

Department of Medical Oncology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing 210002, China.

出版信息

Biomed Pharmacother. 2012 Sep;66(6):397-402. doi: 10.1016/j.biopha.2012.06.002. Epub 2012 Jun 29.

DOI:10.1016/j.biopha.2012.06.002

Abstract

Chemoresistance remains a major obstacle to successful cancer treatment and leads to poor prognosis of the patients, yet the underlying mechanisms have not been fully understood. MicroRNAs (miRNAs) are non-coding small RNAs of 19-22 nucleotides which could negatively regulate gene expressions mainly through 3'-untranslated region (3'UTR) binding of target mRNAs. MiR-200 family (miR-200a, miR-200b, miR-200c, miR-141, and miR-429) is a cluster of miRNAs highly correlated with epithelial-mesenchymal transition (EMT), wherein miR-200b is identified as a critical regulator of tumor invasion, metastasis, and chemosensitivity. Recent advances of miR-200b dysregulation in tumor chemoresistance were summarized. Possible mechanisms and reversion strategies were also addressed.

摘要

化疗耐药仍然是癌症治疗成功的主要障碍，并导致患者预后不良，但其中的机制尚未完全阐明。microRNAs（miRNAs）是一类长度为 19-22 个核苷酸的非编码小分子 RNA，主要通过与靶 mRNAs 的 3'非翻译区（3'UTR）结合来负调控基因表达。miR-200 家族（miR-200a、miR-200b、miR-200c、miR-141 和 miR-429）是与上皮间质转化（EMT）高度相关的 miRNA 簇，其中 miR-200b 被鉴定为肿瘤侵袭、转移和化疗敏感性的关键调节因子。本文总结了 miR-200b 在肿瘤化疗耐药中的失调及其可能的机制和逆转策略。